Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 35 of 37, showing 5 Applications out of 181 total, starting on record 171, ending on 175

# Protocol No Study Title Investigator(s) & Site(s)

171.

ECCT/10/11/06   Randomized Comparison of ART Alone versus ART with Immediate Chemotherapy
    A5264/AMC 067 "A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Li1mited Stage AIDS-KS in Resource-Limited Settings (REACT-KS)"   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Walter Reed Project Kericho (Kericho county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

172.

ECCT/10/11/03   ASMQ Study
    Efficacy, Safety and Population-Pharmacokinetics of Artesunate-Mefloquine Combination for the Treatment of Uncomplicated Falciparum Malaria in African Children versus Artemether-Lumefantrine   
Principal Investigator(s)
1. Bearnhards Ogutu Ragama
Site(s) in Kenya
The Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
 
View

173.

ECCT/10/09/03   A0661201
    A0661201   AN OPEN LABEL, NON-COMPARATIVE STUDY TO EVALUATE PARASITOLOGICAL CLEARANCE RATES AND PHARMACOKINETICS OF AZITHROMYCIN AND CHLOROQUINE FOLLOWING ADMINISTRATION OF A FIXED DOSE COMBINATION OF AZITHROMYCIN AND CHLOROQUINE (AZCQ) IN ASYMPTOMATIC PREGNANT WOMEN WITH PLASMODIUMFALCIPARUM PARASITEMIA IN SUB-SAHARAN AFRICA   
Principal Investigator(s)
1. Joshua Kimani
Site(s) in Kenya
University of Nairobi Institute of Tropical and Infectious Diseases Siaya District Hospital
 
View

174.

ECCT/09/09/02   MAL-58 Study: Protocol no. 112745: SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS\' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN
    SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN   
Principal Investigator(s)
1. LUCAS OTIENO TINA
2. MARY HAMEL
Site(s) in Kenya
1. KEMRI-CDC, (Siaya county)
2. KEMRI-WRP (Kisumu county)
 
View

175.

ECCT/09/03/01   REMoxTB
    A randomised placebo – controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol,  isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and  pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by  two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis   
Principal Investigator(s)
1. Evans Inyangala Amukoye
Site(s) in Kenya
Kibera D.O Health Centre
 
View